Oncology and Hematology
Episodes 33-48 of 87
John Mascarenhas, MD
John Mascarenhas, MD
Gabriela Hobbs, MD
Aiwu Ruth He, MD, PhD
Aiwu Ruth He, MD, PhD
Ghassan K. Abou-Alfa, MD
- MinuteCE®
Emerging First-Line ICI Combination Regimens in Patients With Unresectable HCC
1.00 program creditGhassan K. Abou-Alfa, MD
- MinuteCE®
Pivotal Data Supporting First-Line Atezolizumab/Bevacizumab in Unresectable HCC
1.00 program creditAiwu Ruth He, MD, PhD
Ghassan K. Abou-Alfa, MD
Aiwu Ruth He, MD, PhD
Aiwu Ruth He, MD, PhD
- MinuteCE®
Pivotal Data Supporting First-Line Durvalumab/Tremelimumab in Unresectable HCC
1.00 program creditGhassan K. Abou-Alfa, MD
- MinuteCE®
Use of ICI Combination Regimens in Patients With Intermediate-Stage HCC
1.00 program creditGhassan K. Abou-Alfa, MD
Ghassan K. Abou-Alfa, MD
Aiwu Ruth He, MD, PhD
Ghassan K. Abou-Alfa, MD
Aiwu Ruth He, MD, PhD
Ghassan K. Abou-Alfa, MD
Aiwu Ruth He, MD, PhD
- MinuteCE®
Practice Changing Highlights in G/GEJ Cancers: The Latest Data from Chicago
1.25 program creditsSamuel J. Klempner, MD